Valeant Pharma Trips Over Preliminary Earnings and Guidance

Health and Healthcare

Published: March 15, 2016 10:05 am

Last Updated: January 13, 2020 11:56 am

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported its preliminary fourth-quarter financial results before the markets opened on Tuesday. The company said it had $2.50 in earnings per share (EPS) on $2.8 billion in revenue. That compares to consensus estimates from Thomson Reuters of $2.61 in EPS on $2.75 billion in revenue. The same period from the previous year had $2.58 in EPS on $2.28 billion in revenue.

Note that these results are preliminary results and are subject to change.

It’s also worth mentioning that Valeant’s CEO is on our list of CEOs that need to go.

In terms of guidance for the first quarter, the company expects EPS to be in the range of $1.30 to $1.55 and revenue to total between $2.3 billion and $2.4 billion. The previous guidance given by Valeant predicted that EPS would fall between $2.35 and $2.55 and revenue would be in the range of $2.8 billion to $3.1 billion. The consensus estimates for the first quarter call for $2.63 in EPS on $2.82 billion in revenue.